XML 27 R18.htm IDEA: XBRL DOCUMENT
v3.20.1

12. Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
12. Stockholders' Equity | Dividends Declared Dividends declared and paid on Common Stock were $3,501,366 and $4,279,494 for the years ended December 31, 2019 and 2018, respectively. The Company’s Board of Directors approved a quarterly dividend on February 6, 2020 of $.0625 per share payable in cash on March 13, 2020 to stockholders of record as of February 28, 2020 (see Note 19 - Subsequent Events). Stock Options Pursuant to the Company’s 2005 Equity Participation Plan (the “2005 Plan”), which provides for the issuance of incentive stock options, non-statutory stock options and restricted stock, a maximum of 700,000 shares of the Company’s Common Stock are permitted to be issued pursuant to options granted and restricted stock issued. Effective August 12, 2014, the Company adopted the 2014 Equity Participation Plan (the “2014 Plan”) pursuant to which, a maximum of 700,000 shares of Common Stock of the Company are authorized to be issued pursuant to the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and stock bonuses. Incentive stock options granted under the 2014 Plan and 2005 Plan expire no later than ten years from the date of grant (except no later than five years for a grant to a 10% stockholder). The Board of Directors or the Compensation Committee determines the expiration date with respect to non-statutory stock options and the vesting provisions for restricted stock granted under the 2014 Plan and 2005 Plan. During the year ended December 31, 2018, the remaining options outstanding under the 2005 Plan were exercised and as of December 31, 2018, there were no options outstanding under the 2005 Plan. The results of operations for the years ended December 31, 2019 and 2018 include stock-based compensation expense for stock options totaling approximately $30,000 and $6,000, respectively. Stock-based compensation expense related to stock options is net of estimated forfeitures of approximately 17% for the years ended December 31, 2019 and 2018. Such amounts have been included in the consolidated statements of operations and comprehensive income (loss) within other operating expenses. The weighted average estimated fair value of stock options granted during the year ended December 31, 2019 was $1.91 per share. No options were granted during the year ended December 31, 2018. The fair value of stock options at the grant date was estimated using the Black-Scholes option-pricing model. The following weighted average assumptions were used for grants during the following periods:
|  | Years ended |
|  | December 31, |
|  | 2019 |  |  | 2018 |
Dividend Yield |  |  | 2.87 | % |  |  | n/a |
Volatility |  |  | 36.11 | % |  |  | n/a |
Risk-Free Interest Rate |  |  | 1.61 | % |  |  | n/a |
Expected Life |  |  | 3.25 years |  |  |  | n/a |
The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company’s stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s stock options. A summary of stock option activity under the Company’s 2014 Plan for the year ended December 31, 2019 is as follows:
Stock Options |  | Number of Shares |  |  | Weighted Average Exercise Price per Share |  |  | Weighted Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
Outstanding at January 1, 2019 |  |  | 37,500 |  |  | $ | 8.36 |  |  |  | 2.24 |  |  | $ | 349,950 |
Granted |  |  | 50,000 |  |  | $ | 8.72 |  |  |  |  |  |  | $ | - |
Exercised |  |  | (3,000 | ) |  | $ | 7.85 |  |  |  |  |  |  | $ | 6,270 |
Forfeited |  |  | (2,500 | ) |  | $ | 7.85 |  |  |  | 2.04 |  |  | $ | 13,588 |
Outstanding at December 31, 2019 |  |  | 82,000 |  |  | $ | 8.61 |  |  |  | 3.38 |  |  | $ | - |
Vested and Exercisable at December 31, 2019 |  |  | 50,000 |  |  | $ | 8.45 |  |  |  | 2.12 |  |  | $ | - |
The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2019 is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s Common Stock for the options that had exercise prices that were lower than the $7.75 closing price of the Company’s Common Stock on December 31, 2019. The total intrinsic value of options exercised during the year ended December 31, 2019 was $6,270, determined as of the date of exercise. Participants in the 2014 Plan may exercise their outstanding vested options, in whole or in part, by having the Company reduce the number of shares otherwise issuable by a number of shares having a fair market value equal to the exercise price of the option being exercised (“Net Exercise”), or by exchanging a number of shares owned for a period of greater than one year having a fair market value equal to the exercise price of the option being exercised (“Share Exchange”). The Company received cash proceeds of $23,550 from the exercise of options for the purchase of 3,000 shares of common stock during the year ended December 31, 2019. The Company received cash proceeds of $90,640 from the exercise of options for the purchase of 15,250 shares of common stock during the year ended December 31, 2018. The Company received 7,855 shares from the exercise of options under a Share Exchange for the purchase of 30,000 shares of common stock during the year ended December 31, 2018. The remaining 258,400 options exercised during the year ended December 31, 2018 were Net Exercises, resulting in the issuance of 94,647 shares of common stock. As of December 31, 2019, the estimated fair value of unamortized compensation cost related to unvested stock option awards was approximately $59,000. Unamortized compensation cost as of December 31, 2019 is expected to be recognized over a remaining weighted-average vesting period of 1.74 years. As of December 31, 2019, there were 327,900 shares reserved for grants under the 2014 Plan. Restricted Stock Awards A summary of the restricted Common Stock activity under the Company’s 2014 Plan for the year ended December 31, 2019 is as follows:
Restricted Stock Awards |  | Shares |  |  | Weighted Average Grant Date Fair Value per Share |  |  | Aggregate Fair Value |
Balance at January 1, 2019 |  |  | 120,499 |  |  | $ | 17.66 |  |  | $ | 2,129,175 |
Granted |  |  | 120,586 |  |  | $ | 15.51 |  |  | $ | 1,870,487 |
Vested |  |  | (15,440 | ) |  | $ | 17.04 |  |  | $ | (263,071 | )
Forfeited |  |  | (11,716 | ) |  | $ | 15.57 |  |  | $ | (182,417 | )
Balance at December 31, 2019 |  |  | 213,929 |  |  | $ | 16.51 |  |  | $ | 3,554,174 |
Fair value was calculated using the closing price of the Company’s Common Stock on the grant date. Stock-based compensation expense in 2019 and 2018 includes the estimated fair value of restricted Common Stock granted, amortized on a straight-line basis over the requisite service period. For the years ended December 31, 2019 and 2018, stock-based compensation for these grants was approximately $1,471,500 and $697,000, respectively, which is included in other operating expenses on the accompanying consolidated statements of operations and comprehensive income (loss). These amounts reflect the Company’s accounting expense and do not correspond to the actual value that will be recognized by the directors, executives and employees.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration